Abstract
INTRODUCTION Epidemiological research has suggested that inhibition of tumor necrosis factor (TNF)-α in patients with rheumatoid arthritis (RA) reduces the overall risk of Alzheimer’s disease (AD). TNF-α antagonists have been suggested as a potential treatment for AD.
METHODS We used a two-sample Mendelian randomization design to examine the causal relationship between blood TNF expression, serum TNF-α levels, and RA on AD risk.
RESULTS Our results do not support a causal relationship between TNF expression, serum TNF-α levels or RA on AD risk.
DISCUSSION These results suggest that TNF-α antagonists are unlikely to reduce the risk of AD.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Posted June 19, 2019.
Mendelian randomization indicates that TNF is not causally associated with Alzheimer’s disease
